
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Links:
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica | RheumNow
https://bit.ly/3M0MZ7o
14-10-2023